Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 1;129(7):1287-92.
doi: 10.1242/jcs.182873. Epub 2016 Mar 16.

RAS isoforms and mutations in cancer at a glance

G Aaron Hobbs  1 , Channing J Der  2 , Kent L Rossman  1
Affiliations
Review

RAS isoforms and mutations in cancer at a glance

G Aaron Hobbs et al. J Cell Sci. .

Abstract

RAS proteins (KRAS4A, KRAS4B, NRAS and HRAS) function as GDP-GTP-regulated binary on-off switches, which regulate cytoplasmic signaling networks that control diverse normal cellular processes. Gain-of-function missense mutations in RAS genes are found in ∼25% of human cancers, prompting interest in identifying anti-RAS therapeutic strategies for cancer treatment. However, despite more than three decades of intense effort, no anti-RAS therapies have reached clinical application. Contributing to this failure has been an underestimation of the complexities of RAS. First, there is now appreciation that the four human RAS proteins are not functionally identical. Second, with >130 different missense mutations found in cancer, there is an emerging view that there are mutation-specific consequences on RAS structure, biochemistry and biology, and mutation-selective therapeutic strategies are needed. In this Cell Science at a Glance article and accompanying poster, we provide a snapshot of the differences between RAS isoforms and mutations, as well as the current status of anti-RAS drug-discovery efforts.

Keywords: GTPase; Oncogene; PI3K; Rac; Raf; Ral.

PubMed Disclaimer

Conflict of interest statement

Competing interests

The authors declare no competing or financial interests.

References

    1. Abankwa D., Gorfe A. A. and Hancock J. F. (2008). Mechanisms of Ras membrane organization and signaling: Ras on a rocker. Cell Cycle 7, 2667-2673. 10.4161/cc.7.17.6596 - DOI - PMC - PubMed
    1. Abankwa D., Gorfe A. A., Inder K. and Hancock J. F. (2010). Ras membrane orientation and nanodomain localization generate isoform diversity. Proc. Natl. Acad. Sci. USA 107, 1130-1135. 10.1073/pnas.0903907107 - DOI - PMC - PubMed
    1. Ahearn I. M., Haigis K., Bar-Sagi D. and Philips M. R. (2012). Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 13, 39-51. 10.1038/nrm3255 - DOI - PMC - PubMed
    1. Allegra C. J., Jessup J. M., Somerfield M. R., Hamilton S. R., Hammond E. H., Hayes D. F., McAllister P. K., Morton R. F. and Schilsky R. L. (2009). American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096. 10.1200/JCO.2009.21.9170 - DOI - PubMed
    1. Baker R., Lewis S. M., Sasaki A. T., Wilkerson E. M., Locasale J. W., Cantley L. C., Kuhlman B., Dohlman H. G. and Campbell S. L. (2013a). Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function. Nat. Struct. Mol. Biol. 20, 46-52. 10.1038/nsmb.2430 - DOI - PMC - PubMed

Publication types

MeSH terms